- 236,50$
- Membre: 23179$
Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature, pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.
Section 1: New antibacterial agents.
Chapter 1: New cephalosporins and combinations with β-lactamase inhibitors.
a] Ceftaroline
b] New cephalosporin/β-lactamase inhibitors:
i] Ceftazidime-avibactam; ii] ceftolozane-tazobactam.
1.0. Chemical nature; pharmacology, dosage.
1.1. Microbial spectrum and activity and resistance development
1.2. Advantages over third generation cephalosporins
1.3 Clinical efficacy and indications
1.4. Adverse effects and drug-drug interactions.
1.5. Other comparative agents and cost comparison
Chapter 2: New carbapenem/ β-lactamase inhibitors
i] Meropenem-vaborbactam;
iiI mipenem-cilastin-relabactam
Details as above
Chapter 3: New Glycopeptides , Macrolide and Antibodies
i] Glycopeptides: Oritavancin, dalbavancin and telavancin
ii] Macrolide: Fidaxomicin
iii] Bezlotoxumab for C. difficile colitis
iv] Oblitoxaximab and raxibacumab for anthrax
Details as above
Chapter 4: New Oxazolidinone and Quinolone.
i] Tedizolid
ii] Delafloxacin
As outlined above
Chapter 5: New Tetracyclines
i] Eravacycline;
ii] OmadacyclineAs outlined above
Chapter 6: New Aminoglycoside and new class of antibiotic.
i] Aminoglycoside: Plazomicin
ii] Pleuomutilin [first semisynthetic]: LefamulinHistory of pleuromutilin development.
As outlined above.
Chapter 7: New agents for Tuberculosis
i] Bedaquilineii] Pretomanid
Controversy surrounding pretomanid approval
As outlined above
Section 2: New Antifungal agents.
Chapter 8: New antifungals
i] Present antifungals for systemic infections.ii] New agent: Isavuconazonium
Section 3: New antiparasitic agents
Chapter 9: New agent for Chagas Disease
i] When and what to use for Chagas disease?
ii] Beznidazole for treatment of Chagas disease. As outlined above
Chapter 10: New Drugs for fascioliasis and malaria
I] Agent for fascioliasis: Triclabendazole
Brief review of fascioliasis.
Ii] New antimalarial: tafenoquine
Urgent need for novel antimalarials.
Chapter 11: New agents for Leishmaniasis and Onchocerciasis.
i] Miltefosine for leishmaniasis;
ii] Moxidectin for ochocerciasis.
As outlined above.
Section 4: New antivirals.
Chapter 12. New combinations for HIV-infection.
Review of mode of action of the classes of antiretroviral agents.
i] Single agents: dolutegravir; etravirine, rilpivirine, doravirine, ibalizumab-uik
Ii] Dual combinations: descovy, juluca,
Iii] Triple combinations: triumeq, strbild, genvoya, complera, odefsey, biktarvy, delstrigo, symtuza
Advantages and disadvantages of new combinations and list of fixed combinations.
As outlined above.
Chapter 13. Direct antivirals for hepatitis C.
Mechanisms of action of new hepatitis C drugs.
List of separate drugs and target.
Anti-hepatitis C drugs and fixed combinations.
I] Single agent: daclastavir, simeprevir, sofosbuvir, telepravir, bocepravir
ii]Dual agents: mavyet, epclusa, zepatier, harvoni
iii] Triple agents: vosevi, viekira pak
As outlined above.
Chapter 14. New agents for influenza, cytomegalovirus and smallpox.
Anti-influenza drugs available.
i] New anti-influenza drug -baloxavir.
Ii]New anti-CMV agent--letermovir
Iii] Tecovirimat for smallpox
Chapter 15: New antimicrobials development.
i] Antibiotics in clinical global development
ii] Combination of anti-infectives with enzymes to improve synthetic lethality
iii] Phage therapy
iv] Biotherapy with small molecules
Ignatius Fong is the Editor of Springer's Emerging Infectious Diseases of the 21st Century series. He has served as Chief Editor for six books and the sole author for another six books published in the series. He completed his residency training in Internal Medicine at the University of Toronto and as a Fellow in Infectious Diseases at the University of Washington, Seattle. Dr. Fong has published studies concerning a variety of infectious diseases that include therapeutics and pharmacology of antibiotics, AIDS and the treatment of opportunistic infections, mechanistic and treatment studies of mucosal candidiasis, and pathogenic studies on infection and induction of atherosclerosis in animal models. He was Chief of Infectious Diseases at St. Michael's Hospital (Toronto) for 34 years; he is still on staff in Infectious Diseases and is a Professor of Medicine, Department of Medicine at the University of Toronto, Canada.This is a timely and essential companion to the recently published Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade.Catégories
Caractéristiques
-
- ISBN9783031260773
- Code produitB72008
- ÉditeurSPRINGER PUBLISHING CO.
- Date de publication17 juillet 2023
- FormatPapier
Disponible dans les succursales suivantes
L’inventaire et le prix sont sujets à changement. Nous vous suggérons de contacter Coop Zone avant de vous déplacer:
- 1